Gilead Sciences Inc. / Interius BioTherapeutics, Inc.

B-cell Hematologic Malignancies (in vivo CAR-T)

80K US cases/yr · $4.5B Global CAR-T cell therapy market, 2025 (B-cell malignancies dominant segment) · $368M-$1.5B In vivo CAR-T market 2024 ($368M) projected to $44B by 2034 (InsightAce)

Disease Overview

B-cell hematologic malignancies encompass a heterogeneous group of cancers arising from B-lymphocytes at varying stages of development, including non-Hodgkin lymphomas (NHL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and multiple myeloma. The American Cancer Society projects approximately 80,350 new non-Hodgkin lymphoma cases in the US in 2025, with roughly 85% of NHL subtypes being B-cell in origin and most expressing CD19 or CD20 surface markers that serve as validated CAR-T targets. Diffuse large B-cell lymphoma (DLBCL) alone accounts for about 25,000 new cases annually, with roughly 30-40% relapsing after first-line chemoimmunotherapy. Current ex vivo CAR-T therapies (Yescarta, Kymriah, Breyanzi, Tecartus) have transformed outcomes in relapsed/refractory settings but remain constrained by 3-6 week manufacturing cycles, bridging chemotherapy requirements, lymphodepletion, REMS-restricted academic centers, and $400K-$500K list prices, limiting treatment to roughly 20% of eligible relapsed patients in the US. In vivo CAR-T approaches aim to collapse that access gap via single IV dosing.

Competitive Landscape

The in vivo CAR-T competitive landscape splits across two distinct delivery-technology camps and a dense approved-ex-vivo comparator set. Lentiviral-vector platforms include Interius (INT2104, CD20 via CD7-targeted LV, Phase 1 INVISE in Australia/Europe), Umoja Biopharma (UB-VV111 CD19 and UB-VV400 CD22, partnered with AbbVie via option deal, FDA fast-tracked in R/R B-cell malignancies), and Kelonia Therapeutics (KLN-1010 BCMA for multiple myeloma, Phase 1 in Australia). mRNA lipid-nanoparticle (LNP) platforms include Capstan Therapeutics (CPTX2309 CD19 tLNP, acquired by AbbVie for $2.1B in June 2025), Orna Therapeutics (CD19/BCMA LNP partnered with Merck), and Myeloid Therapeutics (MT-302 circRNA-LNP). Approved ex vivo CAR-T comparators that define the efficacy bar include Gilead/Kite's Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), Novartis' Kymriah (tisagenlecleucel), BMS's Breyanzi (lisocabtagene maraleucel), and J&J/Legend's Carvykti (ciltacabtagene autoleucel). The strategic thesis underlying the Interius acquisition is that in vivo CAR-T can eliminate lymphodepletion, apheresis, and cold-chain manufacturing, broadening CAR-T access from ~20% of eligible relapsed patients to a multiple of that population while defending Kite's incumbent commercial cell therapy franchise against AbbVie's accelerating in vivo platform build.